RecruitingNot ApplicableNCT06351696
The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
The Effects of Low FODMAP Diets Accompanied With and Without Bromelain Supplement on Quality of Life, Disease Activity Index and Inflammation in Patients With Ulcerative Colitis With and Without Primary Sclerosis Cholangitis
Sponsor
National Nutrition and Food Technology Institute
Enrollment
84 participants
Start Date
Apr 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks. IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria2
- active mild to moderate UC
- no other chronic disorders
Exclusion Criteria3
- changed the type and dosage of their medication in the last month
- those who have relapses that required hospitalization and change the type and dosage of medications during the intervention
- patients who do not want to continue the study protocol
Interventions
DIETARY_SUPPLEMENTBromlein
1500 mg/day
OTHERPlacebo
Placebo (1500 mg/day)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06351696
Related Trials
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT0609512849 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744270 locations